Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Other Operating Expenses (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Other Operating Expenses for 15 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses changed N/A year-over-year to $1.9 million, compared with a TTM value of $9.2 million through Dec 2025, changed N/A, and an annual FY2023 reading of -$2.6 million, down 139.61% over the prior year.
  • Other Operating Expenses was $1.9 million for Q4 2025 at Amicus Therapeutics, up from $1.9 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $3.6 million in Q2 2025 and bottomed at -$3.3 million in Q3 2021.
  • Average Other Operating Expenses over 4 years is -$67533.3, with a median of -$337000.0 recorded in 2023.
  • The sharpest move saw Other Operating Expenses crashed 273.71% in 2021, then skyrocketed 352.23% in 2022.
  • Year by year, Other Operating Expenses stood at -$1.7 million in 2021, then grew by 8.65% to -$1.6 million in 2022, then decreased by 25.95% to -$2.0 million in 2023, then surged by 195.09% to $1.9 million in 2025.
  • Business Quant data shows Other Operating Expenses for FOLD at $1.9 million in Q4 2025, $1.9 million in Q3 2025, and $3.6 million in Q2 2025.